Genomic cancer profiling market stays fragmented as NGS and AI drive competition

By AI, Created 4:37 PM UTC, May 18, 2026, /AGP/ – The Business Research Company says the genomic cancer panel and profiling market remains highly fragmented, with Illumina leading 2024 sales and the top 10 players holding just 8% of revenue. The report points to next-generation sequencing, liquid biopsy and AI-driven analysis as the main forces shaping competition through 2035.

Why it matters: - The genomic cancer panel and profiling market is central to precision oncology, where faster and more accurate testing can shape cancer diagnosis and treatment decisions. - The market’s fragmentation gives room for established diagnostics firms and specialized sequencing companies to compete on technology, clinical validation and bioinformatics. - Growth in clinically validated molecular diagnostics, personalized treatment support and regional expansion can shift market share as demand rises.

What happened: - The Business Research Company published a 2026 report on the global genomic cancer panel and profiling market, covering trends and forecasts through 2035. - Illumina Inc. led global sales in 2024 with a 1% market share. - The company’s sequencing and oncology solutions unit offers next-generation sequencing platforms, cancer gene panels, liquid biopsy solutions and bioinformatics tools. - The report identifies major competitors including F. Hoffmann-La Roche Ltd. (Foundation Medicine), Thermo Fisher Scientific Inc., Natera Inc., Guardant Health Inc., Tempus AI Labs, Caris Life Sciences Inc., Agilent Technologies Inc., Invitae Corporation and Myriad Genetics Inc. - The report also lists other major players such as NeoGenomics Inc., Exact Sciences Corporation, Fulgent Genetics Inc., Sysmex Corporation, Hologic Inc., Genscript Biotech Corporation, Burning Rock Biotech Limited, Genecast Biotechnology Co. Ltd, Labcorp, Veracyte Inc., Bruker Corp. (NanoString Technologies Inc.), ARUP Laboratories, Predictive Oncology Inc., 10x Genomics Inc., HTG Molecular Diagnostics Inc. and Personalis Inc.

The details: - The top 10 players accounted for 8% of total market revenue in 2024. - The report says moderate barriers to entry come from clinical validation requirements, genomic data privacy rules, healthcare regulation, sequencing complexity and bioinformatics demands. - Leading companies maintain position through diversified testing portfolios, clinical and research partnerships, global laboratory networks and ongoing product development. - Major raw material suppliers include Illumina, Thermo Fisher Scientific, Agilent Technologies, QIAGEN, Roche, Danaher, Bio-Rad Laboratories, Revvity, BGI Genomics, Oxford Nanopore Technologies, Pacific Biosciences, NanoString Technologies, Hamilton Company, Beckman Coulter Life Sciences, Takara Bio, New England Biolabs, Integrated DNA Technologies, 10x Genomics, Standard BioTools, Eurofins Scientific, GenScript Biotech, Azenta Life Sciences, LGC and Twist Bioscience. - Major wholesalers and distributors include McKesson, Cardinal Health, Cencora, Medline Industries, Henry Schein, Owens & Minor, Avantor, VWR International, Medipal Holdings, Sinopharm Group, Shanghai Pharmaceuticals, Zuellig Pharma, Phoenix Pharmahandel, Movianto, Uniphar Group, H. D. Smith Wholesale Drug Co., Morris & Dickson, Anda, CuraScript SD and Alloga. - Major end users include Apollo Hospitals Enterprise Limited, Fortis Healthcare Limited, HCG Cancer Centre, Mount Sinai Health System, Kaiser Permanente, Cleveland Clinic Abu Dhabi and King Faisal Specialist Hospital & Research Centre. - The report includes a sample request link: Request a free sample. - The full report is available here: Access the detailed report.

Between the lines: - The market’s low concentration suggests no single vendor has broad control, even as the largest players build around end-to-end cancer testing stacks. - The focus on AI-driven genomic data analysis points to a shift from raw sequencing toward interpretation, where software and workflow integration may matter as much as wet-lab hardware. - The April 2025 launch of QIAGEN N.V.’s QIAseq panels, designed for next-generation sequencers, shows how vendors are targeting broader gene coverage and faster analysis to compete. - QIAGEN said the panels support analysis of more than 700 genes for cancer research and clinical applications.

What’s next: - Next-generation sequencers are likely to keep pushing diagnostic speed and accuracy higher. - Multi-gene panels and liquid biopsy tools should remain key competitive areas as cancer profiling moves deeper into routine clinical use. - Companies are expected to lean more on AI, automation and integrated bioinformatics to strengthen precision oncology offerings. - Strategic collaborations and geographic expansion may matter more as buyers seek clinically validated systems and scalable laboratory support.

The bottom line: - The genomic cancer panel and profiling market is still crowded and highly fragmented, but the winners are building around sequencing depth, data interpretation and clinical credibility.